Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Henri Mondor University Hospital
Hydroxychloroquine (HCQ) is usually used in Patients with Systemic Lupus Erythematosus (SLE) in order to treat mainly arthralgia or skin manifestations of this disease. A few studies have previously shown that HCQ could also be useful for treating autoimmune cytopenia and particularly autoimmune thrombopenia associated with SLE. In this retrospective study, the investigators have selected patients followed in our center and who have received HCQ either for an authentic SLE or because they had positive antinuclear antibodies (\> 1/160e on HEP2 cells) without a definite SLE according to the American College of Rheumatology.
The main goal of this study is to compare the efficacy of HCQ in these two subgroups of patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients older than 18 years old
Immune Thrombopenia according to the American Society of Hematology (ASH) guidelines 2011
Positive antinuclear antibodies \> 1/160e on Hep2 cells
